We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Application of PPAR Ligands and Nanoparticle Technology in Metabolic Steatohepatitis Treatment.
- Authors
Vu, Hung Thai; Nguyen, Vien Duc; Ikenaga, Hiroko; Matsubara, Tsutomu
- Abstract
Metabolic dysfunction-associated steatotic liver disease/steatohepatitis (MASLD/MASH) is a major disease worldwide whose effective treatment is challenging. Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear receptor superfamily and function as ligand-activated transcription factors. To date, three distinct subtypes of PPARs have been characterized: PPARα, PPARβ/δ, and PPARγ. PPARα and PPARγ are crucial regulators of lipid metabolism that modulate the transcription of genes involved in fatty acid (FA), bile acid, and cholesterol metabolism. Many PPAR agonists, including natural (FAs, eicosanoids, and phospholipids) and synthetic (fibrate, thiazolidinedione, glitazar, and elafibranor) agonists, have been developed. Furthermore, recent advancements in nanoparticles (NPs) have led to the development of new strategies for MASLD/MASH therapy. This review discusses the applications of specific cell-targeted NPs and highlights the potential of PPARα- and PPARγ-targeted NP drug delivery systems for MASLD/MASH treatment.
- Subjects
PEROXISOME proliferator-activated receptors; TRANSCRIPTION factors; DRUG delivery systems; CHOLESTEROL metabolism; BILE acids
- Publication
Biomedicines, 2024, Vol 12, Issue 8, p1876
- ISSN
2227-9059
- Publication type
Article
- DOI
10.3390/biomedicines12081876